Literature DB >> 31235263

Structure-based design of potent linear peptide inhibitors of the YAP-TEAD protein-protein interaction derived from the YAP omega-loop sequence.

Pascal Furet1, Bahaa Salem2, Yannick Mesrouze2, Tobias Schmelzle2, Ian Lewis2, Joerg Kallen2, Patrick Chène2.   

Abstract

The YAP-TEAD protein-protein interaction is a potential therapeutic target to treat cancers in which the Hippo signaling pathway is deregulated. However, the extremely large surface of interaction between the two proteins presents a formidable challenge for a small molecule interaction disrupter approach. We have accomplished progress towards showing the feasibility of this approach by the identification of a 15-mer peptide able to potently (nanomolar range) disrupt the YAP-TEAD interaction by targeting only one of the two important sites of interaction. This peptide, incorporating non-natural amino acids selected by structure-based design, is derived from the Ω-loop sequence 85-99 of YAP.
Copyright © 2019 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Anticancer drug target; Protein-protein interaction (PPI) inhibitors; Structure-based design

Mesh:

Substances:

Year:  2019        PMID: 31235263     DOI: 10.1016/j.bmcl.2019.06.022

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  8 in total

Review 1.  Context-dependent roles of YAP/TAZ in stem cell fates and cancer.

Authors:  Lucy LeBlanc; Nereida Ramirez; Jonghwan Kim
Journal:  Cell Mol Life Sci       Date:  2021-02-13       Impact factor: 9.261

Review 2.  The YAP/TAZ Pathway in Osteogenesis and Bone Sarcoma Pathogenesis.

Authors:  Heinrich Kovar; Lisa Bierbaumer; Branka Radic-Sarikas
Journal:  Cells       Date:  2020-04-15       Impact factor: 6.600

Review 3.  Recent Therapeutic Approaches to Modulate the Hippo Pathway in Oncology and Regenerative Medicine.

Authors:  Evan R Barry; Vladimir Simov; Iris Valtingojer; Olivier Venier
Journal:  Cells       Date:  2021-10-11       Impact factor: 6.600

Review 4.  Assays Used for Discovering Small Molecule Inhibitors of YAP Activity in Cancers.

Authors:  Subhajit Maity; Artem Gridnev; Jyoti R Misra
Journal:  Cancers (Basel)       Date:  2022-02-17       Impact factor: 6.639

5.  Aurintricarboxylic acid is a canonical disruptor of the TAZ-TEAD transcriptional complex.

Authors:  Kepeng Che; Ajaybabu V Pobbati; Caleb N Seavey; Yuriy Fedorov; Anton A Komar; Ashley Burtscher; Shuang Ma; Brian P Rubin
Journal:  PLoS One       Date:  2022-04-13       Impact factor: 3.240

6.  A Drosophila model of oral peptide therapeutics for adult intestinal stem cell tumors.

Authors:  Anjali Bajpai; Taushif Ahmad Quazi; Hong-Wen Tang; Nishat Manzar; Virender Singh; Ashwani Thakur; Bushra Ateeq; Norbert Perrimon; Pradip Sinha
Journal:  Dis Model Mech       Date:  2020-07-23       Impact factor: 5.758

7.  TEAD-YAP Interaction Inhibitors and MDM2 Binders from DNA-Encoded Indole-Focused Ugi Peptidomimetics.

Authors:  Verena B K Kunig; Marco Potowski; Mohammad Akbarzadeh; Mateja Klika Škopić; Denise Dos Santos Smith; Lukas Arendt; Ina Dormuth; Hélène Adihou; Blaž Andlovic; Hacer Karatas; Shabnam Shaabani; Tryfon Zarganes-Tzitzikas; Constantinos G Neochoritis; Ran Zhang; Matthew Groves; Stéphanie M Guéret; Christian Ottmann; Jörg Rahnenführer; Roland Fried; Alexander Dömling; Andreas Brunschweiger
Journal:  Angew Chem Int Ed Engl       Date:  2020-07-15       Impact factor: 16.823

8.  Study of the TEAD-binding domain of the YAP protein from animal species.

Authors:  Yannick Mesrouze; Fedir Bokhovchuk; Marco Meyerhofer; Catherine Zimmermann; Patrizia Fontana; Dirk Erdmann; Patrick Chène
Journal:  Protein Sci       Date:  2020-11-20       Impact factor: 6.993

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.